Dietary approaches produce much more modest effects than prescription GLP-1 medications
severe or persistent upper abdominal pain should prompt urgent medical assessment [10] [11] Dehydration and acute kidney injury (AKI): gastrointestinal fluid losses can lead to dehydration, which may precipitate AKI, particularly in those with pre-existing renal impairment or those taking nephrotoxic medicines Delayed gastric emptying: this may affect the absorption of orally administered medicines, including contraceptive pills and thyroid replacement therapy [11] Injection site reactions: redness, bruising, or discomfort at the subcutaneous injection site Heart rate changes: increases in resting heart rate have been noted with GLP-1 class agents [14] [15] Hypoglycaemia: particularly if used alongside insulin or sulphonylureas Potential pancreatitis risk: a class concern with GLP-1 receptor agonists
There are currently no documented or clinically supported benefits associated with a 60 mg dose of Retatrutide
Medication leaking back out Sometimes after removing the needle, a small amount of clear fluid appears at the injection site
However, retatrutide remains an investigational therapy, and its long-term safety, efficacy, and place in clinical practice will depend on complete peer-reviewed data, results from ongoing Phase 3 studies, and regulatory review
It simply became more noticeable
